If we can’t sign any kind of deal, it just straight-up looks...

If we can’t sign any kind of deal, it just straight-up looks like nobody in the biopharma sphere rates this as an opportunity at all. VC will want a large part of the company. To fund PAR through trials? AU$90m+? How much is there to even give up? It’s not a float where you can get a bunch of retail mugs and noobs to buy what you’re selling and asking for no control in return, VC will be trying for nothing else than to maximise their profit from PAR, and they’ll want control to protect their investment. At these prices, isn’t asking VC to fund trials tantamount to a takeover at our weakest moment? And if they are not funding trials entirely…then it’s nothing but a Hail Mary that deal suitors will be dazzled by Interim Readout, which is the same thinking the board showed when they thought the market would be dazzled by 008 and re-rate PAR. Instead the market cap just continued to plummet because the only thing the market wants/needs to see is that PAR can exhibit some modicum of self-sufficiency, and that can only be shown via a deal.